

Dated-11.11.2022

BSE LIMITED
Corporate Relations Department
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai-400001
Scrip code: 543264

NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Listing Department
Exchange Plaza, 5th Floor, Plot no. C/1
G Block, Bandra Kurla Complex, Bandra (E)
Mumbai-400051
Scrip Code: NURECA

Subject: Outcome of Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at the Meeting held today i.e. November 11, 2022 (Friday) have –

1. Approved the unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2022.

Copies of the unaudited Standalone and Consolidated Financial Results along with Limited Review Reports from the Company's Statutory Auditors are enclosed herewith.

2. Approved the amendment in the Company's "Code of Conduct for Prevention of Insider Trading" to align the same with the amendment in the SEBI (Prohibition of Insider Trading) Regulations. The amended Code of Conduct for Prevention of Insider Trading will be available on the website of the Company (www.nureca.com).

Presentation on financial results for the quarter and half-year ended September 30, 2022 is also enclosed.

The Board Meeting commenced at 5:00 PM and concluded at 6:30 P.M.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,
For Nureca Limited

Chetna Anand

(Chetna Anand)

Company Secretary & Compliance Officer



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868


NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2022

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2022 (Unaudited)	30 June 2022 (Unaudited)	30 September 2021 (Unaudited)	30 September 2022 (Unaudited)	30 September 2021 (Unaudited)	31 March 2022 (Audited)
1	Revenue from operations	367.86	260.60	469.10	628.46	1,663.92	2,555.49
2	Other income	19.13	11.75	21.21	30.88	42.60	77.20
3	Total income (1+2)	386.99	272.35	490.31	659.34	1,706.52	2,632.69
4	Expenses						
	Purchase of stock-in-trade	132.25	126.98	502.54	259.23	999.32	1,595.34
	Changes in inventories of stock-in-trade	143.64	48.38	(222.06)	192.02	(224.41)	(269.16)
	Employee benefits expense	48.52	41.89	22.87	90.41	47.99	98.31
	Finance costs	0.99	1.29	1.24	2.28	3.41	7.31
	Depreciation and amortization expense	6.00	5.90	3.02	11.90	4.48	14.32
	Other expenses	91.87	98.29	105.09	190.16	309.97	573.27
	Total expenses	423.27	322.73	412.70	746.00	1,140.76	2,019.39
5	(Loss)/profit before income tax (3-4)	(36.28)	(50.38)	77.61	(86.66)	565.76	613.30
6	Tax expense						
	- Current tax	-	-	22.18	-	149.69	155.70
	- Deferred tax (credit)/charge	(8.44)	(11.71)	0.57	(20.15)	(0.32)	4.51
7	Net (loss)/profit after income tax (5-6)	(27.84)	(38.67)	54.86	(66.51)	416.39	453.09
8	Other comprehensive income/(expense)						
A	(i) Item that will not be reclassified to profit or loss	0.48	0.48	0.07	0.96	0.10	1.90
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.12)	(0.12)	(0.02)	(0.24)	(0.03)	(0.48)
B	(i) Item that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive (loss)/income for the period/ year (7+8)	(27.48)	(38.31)	54.91	(65.79)	416.46	454.51
10	(Loss)/earnings per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized)	(2.78)	(3.87)	5.49	(6.65)	41.64	45.31
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00	100.00
12	Reserve (excluding revaluation reserve) See accompanying notes to the unaudited standalone financial results						1,937.43



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868


NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of Standalone Assets and Liabilities

Sr. No.	Particulars	As at	
		30 September 2022 (Unaudited)	31 March 2022 (Audited)
	Assets		
(1)	Non-current assets		
	Property, plant and equipment	29.66	32.68
	Right-of-use assets	35.12	41.19
	Intangible assets	26.76	23.92
	Intangible assets under development	-	4.23
	Financial assets		
	- Investments	30.56	13.06
	- Loans	13.40	-
	- Other financial assets	2.70	22.14
	Deferred tax assets (net)	21.16	1.01
	Incom tax assets (net)	15.70	-
	Total non-current assets	175.06	138.23
(2)	Current assets		
	Inventories	442.31	631.66
	Financial assets		
	- Investments	526.37	331.86
	- Trade receivables	34.53	28.68
	- Cash and cash equivalents	6.96	81.58
	- Bank balances other than cash and cash equivalents	739.44	760.28
	- Other financial assets	70.84	67.38
	Other current assets	130.43	155.68
	Total current assets	1,950.88	2,057.12
	Total assets (1+2)	2,125.94	2,195.35
(1)	Equity		
	Equity share capital	100.00	100.00
	Other equity	1,871.64	1,937.43
	Total equity	1,971.64	2,037.43
(2)	Non-current liabilities		
	Financial liabilities		
	- Lease liabilities	26.76	32.81
	Provisions	5.83	4.14
	Total non-current liabilities	32.59	36.95
(3)	Current liabilities		
	Financial liabilities		
	- Lease liabilities	11.20	10.48
	- Trade payables		
	- total outstanding dues of micro and small enterprises	1.23	3.61
	- total outstanding dues of creditors other than micro and small enterprises	67.36	43.38
	- Other financial liabilities	0.14	0.07
	Other current liabilities	38.34	41.20
	Provisions	3.44	1.69
	Current tax liabilities (net)	-	20.54
	Total current liabilities	121.71	120.97
	Total liabilities (2+3)	154.30	157.92
	Total equity and liabilities (1+2+3)	2,125.94	2,195.35



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED			
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868			
<i>(Amount in INR million, unless otherwise stated)</i>			
Statement of Standalone Cash Flow			
Sr. No.	Particulars	For the	
		Half year ended 30 September 2022 (Unaudited)	Half year ended 30 September 2021 (Unaudited)
	Cash flows from operating activities		
	(Loss)/profit before tax for the period	(86.66)	565.77
	Adjustments for:		
	Depreciation expense	11.90	4.48
	Income on unwinding of security deposits	(0.06)	-
	Unrealized foreign exchange (gain)	(0.13)	(0.05)
	Finance costs	2.28	3.41
	Interest income	(21.45)	(31.84)
	Unrealized gain on mutual funds	(6.83)	(1.73)
	Operating cash flows before working capital changes	(100.95)	540.04
	Working capital adjustments		
	Decrease/(increase) in inventories	189.35	(223.05)
	(Increase) in trade receivables	(5.85)	(74.40)
	Increase in trade payables	21.73	42.51
	Decrease/(increase) in other assets	33.18	(44.00)
	(Decrease) in other current liabilities	(2.86)	(6.37)
	Increase in provisions	4.40	0.34
	Cash generated from operating activities	139.00	235.07
	Income tax paid (net)	(36.24)	(123.85)
(A)	Net cash generated from operating activities	102.76	111.22
	Cash flows from investing activities		
	Purchase of property, plant and equipment	(1.42)	(15.18)
	Purchase of Intangible Assets under development	-	(4.19)
	Interest income received	9.89	24.16
	Investment in subsidiary	(17.50)	-
	Purchase of mutual funds	(206.18)	(117.38)
	Sale of mutual funds	18.50	-
	Unsecured Loan to subsidiaries	(13.40)	-
	Fixed deposits redeemed / (placed)	40.34	(35.61)
(B)	Net cash used in investing activities	(169.77)	(148.20)
	Cash flows from financing activities		
	Payment of lease liabilities (including interest)	(7.07)	(3.37)
	Interest paid	(0.54)	(2.27)
	Repayment of non-current borrowings	-	(7.79)
	Repayment of current borrowings (net)	-	(1.46)
(C)	Net cash used in financing activities	(7.61)	(14.89)
(A+B+C)	Net (decrease) in cash and cash equivalents	(74.62)	(51.87)
	Cash and cash equivalents at the beginning of the year	81.58	169.99
	Cash and cash equivalents at the end of the period	6.96	118.12
	Components of cash and cash equivalents		
	Balances with banks		
	- In current accounts	6.96	118.12
	Total cash and cash equivalents	6.96	118.12



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED


Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868


Notes to the unaudited standalone financial results:

- 1 The above unaudited standalone financial results for the quarter and half year ended 30 September 2022 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 11 November 2022. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- 2 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products.
- 3 On 20 May 2022, the Company had invested INR 17.5 million on right issue basis in its wholly owned subsidiary i.e. Nureca Technologies Private Limited.

Place: Chandigarh
Date: 11 November 2022

For and on behalf of Board of Directors of
Nureca Limited


Saurabh Goyal
(Managing Director)
DIN : 00136037




NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED							
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868							
(Amount in INR million, unless otherwise stated)							
Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30 September 2022							
Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2022 (Unaudited)	30 June 2022 (Unaudited)	30 September 2021 (Unaudited)	30 September 2022 (Unaudited)	30 September 2021 (Unaudited)	31 March 2022 (Audited)
1	Revenue from operations	367.81	255.28	469.40	623.09	1,664.22	2,555.48
2	Other income	18.90	11.71	21.10	30.61	42.49	76.95
3	Total income (1+2)	386.71	266.99	490.50	653.70	1,706.71	2,632.43
4	Expenses						
	Purchase of stock-in-trade	137.33	128.86	502.55	266.19	999.33	1,595.51
	Changes in inventories of stock-in-trade	136.83	41.95	(222.06)	178.78	(224.41)	(269.27)
	Employee benefits expense	50.03	42.79	22.91	92.82	48.06	99.14
	Finance costs	1.02	1.35	1.24	2.37	3.43	7.41
	Depreciation and amortization expense	6.19	6.07	3.12	12.26	4.67	14.82
	Other expenses	92.70	98.97	105.66	191.67	309.97	575.01
	Total expenses	424.10	319.99	413.42	744.09	1,141.05	2,022.62
5	(Loss)/profit before income tax (3-4)	(37.39)	(53.00)	77.08	(90.39)	565.66	609.81
6	Tax expense						
	- Current tax	-	-	22.17	-	149.68	155.70
	- Deferred tax (credit)/charge	(8.47)	(11.71)	0.57	(20.18)	(0.32)	4.51
7	Net (loss)/profit after income tax (5-6)	(28.92)	(41.29)	54.34	(70.21)	416.30	449.60
8	Other comprehensive income/(expense)						
A	(i) Item that will not be reclassified to profit or loss	0.48	0.48	0.07	0.96	0.10	1.90
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.12)	(0.12)	(0.02)	(0.24)	(0.03)	(0.48)
B	(i) Item that will be reclassified to profit or loss	(0.01)	(0.02)	0.00	(0.03)	0.00	(0.01)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income for the period/year (net of tax)	0.35	0.34	0.05	0.69	0.07	1.41
9	Total comprehensive (loss)/income for the period/year (7+8)	(28.57)	(40.95)	54.39	(69.52)	416.37	451.01
10	(Loss)/earnings per share of Rs. 10 each						
	- Basic and diluted (in rupees) (not annualized)	(2.89)	(4.13)	5.43	(7.02)	41.63	44.96
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00	100.00
12	Reserve (excluding revaluation reserve)						1,931.98
	See accompanying notes to the unaudited consolidated financial results						



NURECA LIMITED


Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of consolidated Assets and Liabilities		As at	
Sr. No.	Particulars	30 September 2022 (Unaudited)	31 March 2022 (Audited)
	Assets		
(1)	Non-current assets		
	Property, plant and equipment	33.85	36.78
	Right-of-use assets	35.12	41.19
	Intangible assets	27.64	23.92
	Intangible assets under development	-	4.23
	Financial assets		
	- Other financial assets	2.80	22.24
	Deferred tax assets (net)	21.15	1.01
	Income tax assets (net)	15.72	-
	Total non-current assets	136.28	129.37
(2)	Current assets		
	Inventories	455.66	631.77
	Financial assets		
	- Investments	526.37	331.86
	- Trade receivables	27.51	28.94
	- Cash and cash equivalents	13.42	82.49
	- Bank balances other than cash and cash equivalents	739.44	761.03
	- Other financial assets	70.68	67.38
	Other current assets	140.73	158.46
	Total current assets	1,973.81	2,061.93
	Total assets (1+2)	2,110.09	2,191.30
(1)	Equity		
	Equity share capital	100.00	100.00
	Other equity	1,862.46	1,931.98
	Total equity	1,962.46	2,031.98
(2)	Non-current liabilities		
	Financial liabilities		
	- Lease liabilities	26.76	32.81
	Provisions	5.94	4.13
	Total non-current liabilities	32.70	36.94
(3)	Current liabilities		
	Financial liabilities		
	- Borrowings	0.79	0.76
	- Lease liabilities	11.20	10.48
	- Trade payables		
	- total outstanding dues of micro and small enterprises	1.23	3.61
	- total outstanding dues of creditors other than micro and small enterprises	58.97	43.60
	- Other financial liabilities	0.34	0.22
	Other current liabilities	38.88	41.44
	Provisions	3.52	1.69
	Current tax liabilities (net)	-	20.58
	Total current liabilities	114.93	122.38
	Total liabilities (2+3)	147.63	159.32
	Total equity and liabilities (1+2+3)	2,110.09	2,191.30



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN E24304MH2016PLC320868


NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
 Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
 Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of consolidated Cash Flow

Sr. No.	Particulars	For the	
		Half year ended 30 September 2022 (Unaudited)	Half year ended 30 September 2021 (Unaudited)
	Cash flows from operating activities		
	(Loss)/profit before tax for the period	(90.39)	565.66
	Adjustments for:		
	Depreciation expense	12.26	4.67
	Income on unwinding of security deposits	(0.06)	(0.02)
	Unrealized foreign exchange (gain)	(0.13)	(0.05)
	Finance costs	2.37	3.43
	Interest income	(21.30)	(31.84)
	Unrealized gain on mutual funds	(6.83)	(1.73)
	Operating cash flows before working capital changes	(104.08)	540.12
	Working capital adjustments		
	Decrease/(increase) in inventories	176.11	(222.38)
	Decrease/(increase) in trade receivables	1.43	(74.69)
	Increase in trade payables	13.12	42.77
	Decrease/(increase) in other current assets	25.63	(45.99)
	(Decrease) in other financial liabilities	(0.07)	-
	(Decrease) in other current liabilities	(2.56)	(6.38)
	Increase in provisions	4.60	0.34
	Cash generated from operating activities	114.18	233.79
	Income tax paid (net)	(36.30)	(123.88)
(A)	Net cash generated from operating activities	77.88	109.91
	Cash flows from investing activities		
	Purchase of property, plant and equipment	(1.84)	(15.18)
	Purchase of intangibles asset under development	-	(4.19)
	Purchase of Intangible Assets	(0.91)	-
	Interest income received	9.90	24.16
	Purchase of mutual funds	(206.18)	(117.37)
	Sale of mutual funds	18.51	-
	Fixed deposits redeemed / (placed)	41.23	(35.61)
(B)	Net cash used in investing activities	(139.29)	(148.19)
	Cash flows from financing activities		
	Payment of lease liabilities (including interest)	(7.08)	(3.35)
	Interest paid	(0.58)	(2.28)
	Repayment of non-current borrowings	-	(7.79)
	Proceeds from/(repayment) of current borrowings (net)	0.03	(1.45)
(C)	Net cash used in financing activities	(7.63)	(14.87)
(A+B+C)	Net (decrease) in cash and cash equivalents	(69.04)	(53.15)
	Effect of exchange rate fluctuations on cash & cash equivalents held in foreign currency	(0.03)	-
	Cash and cash equivalents at the beginning of the year	82.49	172.42
	Cash and cash equivalents at the end of the period	13.42	119.27
	Components of cash and cash equivalents		
	Balances with banks:		
	- In current accounts	7.62	119.27
	- Fixed deposits with original maturity upto three months	5.80	-
	Total cash and cash equivalents	13.42	119.27



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
 Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
 Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868


NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 40063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited consolidated financial results:

- 1 The above unaudited consolidated financial results for the quarter and half year ended 30 September 2022 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 11 November 2022. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- 2 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products

For and on behalf of Board of Directors of
Nureca Limited



Saurabh Goyal
(Managing Director)
DIN : 00136037

Place: Chandigarh
Date: 11 November 2022

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 40063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

B S R & Co. LLP

Chartered Accountants

Unit No. A505 (A),
5th Floor, Plot No.178-178A,
Industrial & Business Park,
Phase -1, Chandigarh-160002

Telephone: +91 172 664 4000
Fax: +91 172 664 4004

Limited Review Report on unaudited standalone financial results of Nureca Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015


To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nureca Limited ("the Company") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Ankush Goel

Partner

New Delhi

11 November 2022

Membership No.: 505121

UDIN:22505121BCVSSF7962

B S R & Co. LLP

Chartered Accountants

Unit No. A505 (A),
5th Floor, Plot No.178-178A,
Industrial & Business Park,
Phase -1, Chandigarh-160002

Telephone: +91 172 664 4000
Fax: +91 172 664 4004

Limited Review Report on unaudited consolidated financial results of Nureca Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nureca Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities :
 - a. Nureca Limited- Parent Company (incorporated in India)
 - b. Nureca INC- Subsidiary Company (incorporated in U.S.A.)
 - c. Nureca Healthcare Private Limited- Subsidiary Company (incorporated in India)
 - d. Nureca Technologies Private Limited, India- Subsidiary Company (incorporated in India)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Ag

Registered Office:

B S R & Co. LLP


6. The Statement includes the interim financial information of three subsidiaries which have not been reviewed, whose interim financial information reflect total assets (before consolidation adjustment) of Rs. 45.39 million as at 30 September 2022, total revenues (before consolidation adjustment) of Rs. 8.26 million and Rs. 8.26 million, total net (loss) after tax (before consolidation adjustment) of Rs. (1.03 million) and Rs. (3.65 million) and total comprehensive loss (before consolidation adjustment) of Rs. (1.03 million) and Rs. (3.65 million) for the quarter ended 30 September 2022 and for the period from 1 April 2022 to 30 September 2022, and cash flows (net) of Rs. 5.55 million for the period from 1 April 2022 to 30 September 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248WW-100022



Ankush Goel

Partner

New Delhi

11 November 2022

Membership No.: 505121

UDIN:22505121BCVTDL7660

NUREÇA

Think.
Feel.
Create.



+ Earnings Presentation
November 2022

Disclaimer

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the healthcare industry, increasing competition, changes in political conditions in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Nureca Ltd.

NURECA,
is a leading Digital
healthcare and wellness
Solutions provider



CHRONIC
DISEASES



LIFESTYLE
& FITNESS



ORTHO CARE



MOTHER
& BABY



NUTRITION

Our
Focus
Areas

2021

Listed On Stock
Exchanges

₹ 50 CR

GMV For Q2FY23

₹ 39 CR

Total Revenue For
Q2FY23

50+

USFDA Approved
Products

₹ (3) CR

EBITDA For Q2FY23

₹ (3) CR

PAT For Q2FY23

03

Established Brands

DrTrust DR PHYSIO trumom

210+ SKUS

Respiratory,
Physiotherapy,
Cardiac, Diabetes
And Mother & Child
Care




Our growing customer base

CUSTOMER BASE

(CUMULATIVE)*


(000')



STEADY

IMPROVEMENT IN REPEAT CUSTOMER

Returning visitors to our website



Our customer base has grown exceptionally over the last 4 years which is a result of remarkable quality of our products that led to word-of-mouth marketing by our loyal customer base. Currently, most of our products enjoy 4+ Star ratings out of 5-star ratings across e-commerce platform.


At Nureca, we have a focused marketing strategy to grow our brands and our advertisement expenditure in the range of 3-5% of our revenue which lower compared to the Industry average.

*Gross Market Volume

Financial Updates


GMV

(INR mn)



Operating Revenue

(INR mn)




- ✓ GMV of H1'FY23 stood at Rs. 841 mn as compared to Rs. 2285 Mn in H1'FY22, decrease of 63%
- ✓ Operating Revenue was Rs. 623 mn in H1'FY23 as compared to Rs. 1,664 in H1'FY22, decrease of 63%
- ✓ Overall, demand has seen a dip in H1'FY23 as compared to the same period last year, which had seen a huge surge in demand due to Covid-19
- ✓ Our Gross margins in H1'FY23 were impacted due to lower demand, inflation in input cost, currency fluctuation as well as inflationary pressure in other non-core costs such as packaging, transport, etc.
- ✓ Our employee cost has increased as compared to the same quarter last year due to aggressive talent acquisition across the business functions and verticals majorly for app development and expansion of Offline distribution network.
- ✓ Other expenses are lower in H1'FY23 by 38%, as the variable cost decreased in line with the top line.
- ✓ Overall, EBITDA was Rs. (30) mn in Q2'FY23 and PAT stood at Rs. (29) mn


Key Performance Indicators

EBITDA & EBITDA MARGIN


(INR mn)



EPS




PAT & PAT MARGIN



Return Ratios

(INR mn)



Note: ROCE derived on basis of average equity and average capital employed

Financials – Income Statement

(INR mn)

Particulars	Q2'FY22	Q1'FY23	Q2'FY23	% Q2'FY23 vs Q1'FY23	% Q2'FY23 vs Q2'FY22
Revenue from operations	469	255	368	44%	-22%
Other Income	21	12	19	61%	-10%
Total Revenue	491	267	387	45%	-21%
Cost of Goods Sold	280	171	274	61%	-2%
Employee benefits expense	23	43	50	17%	118%
Other expenses	106	99	93	-6%	-12%
Total Expenses	409	313	417	33%	2%
EBITDA	81	-46	-30	34%	-137%
Finance Cost	1	1	1	-24%	-18%
Depreciation	3	6	6	2%	98%
PBT	77	-53	-37	29%	-149%
Current tax	22	-	-	-	-
Deferred tax	1	-12	-8	-28%	-1586%
PAT	54	-41	-29	30%	-153%

New Product Launches

DR TRUST[®] - Orthopedic Heat belt 346

In the recently concluded quarter, we launched Orthopedic Heat Belt 346 under our Dr Trust Brand. This easy-to-use heating belt provides warming effects and relaxation to the affected body parts and reduces pain. It has an inbuilt dual thermostat plus 4 layers of insulation to ensure safety and comfort. Further, its soft and washable cover is easy to clean and maintain.

This universal size belt fits all and ensures a firm hold through a long velcro strap. It has an adjustable 3 remote-controlled temperature setting up to 85 °C and a 2.45 m extra-long connecting cable for the varied needs of each user. This is suitable for those dealing with backache, period cramps, sore muscles, stiff joints, or other body pain issues that make it difficult for them to carry out everyday activities.



Smart Products Portfolio –

DrTrust 36

*Our devices are clinically accurate
USFDA & CE Approved



Body composition scales



BP monitors



Glucometers



ECG monitor



Smartwatches



Pulse Oximeter

Health metrics captured from devices:

Weighing scale*

- Bone Mass
- BMI & BMR
- Subcutaneous Fat
- Body Fat %
- Muscle Mass & Rate
- Protein Mass
- Visceral Fat
- Body Water %
- Metabolic Age
- Age
- Height

BP Monitor*

- Systolic BP
- Diastolic BP
- Pulse Rate
- Age
- Height
- Body weight

Glucometer*

- Fasting
- After Meal
- Before Meal
- Random
- Age
- Height
- Body weight

ECG monitor*

- Electrocardiogram
- Heart rhythm
- Heartbeat rate
- Age
- Height
- Body weight

Smartwatches


- Health Monitoring
- Body Temperature
- SpO2
- Heart Rate
- Blood Pressure
- HRV & Stress Level
- Tracking fitness with multisport mode

Pulse Oximeter*

- SpO2
- Heart Rate

Our AI driven platform –

DrTrust 360





DrTrust 360

Manage Not Monitor





The No. 1 App For A Holistic Health Management Experience.
Don't just Monitor Your Health,
Manage It With Dr Trust 360.

Syncs With





DrTrust 360

SMART SENSEI TECHNOLOGY

-  One app for all Dr Trust Smart Devices
-  Stay connected with doctors with easy data sharing
-  Clinically approved holistic health recommendations
-  Easy to use technology with class leading features


Syncs With



DrTrust 360

1 APP 360° Solutions

The future of smart healthcare reimagined. With a wide range of smart connected devices by Dr Trust, now managing your health is easier than ever before. Download the Dr Trust 360 App and experience holistic healthcare solutions for all your lifestyle needs.



DrTrust 360

Manage Not Monitor

SMART SENSEI TECHNOLOGY

The Future Of Connected Healthcare

Choose from a wide range of smart devices by Dr Trust and stay connected with good health.



Blood Pressure Monitors

Blood Glucose Monitors

Digital Weighing Scale

Our connected health solution – DrTrust 360

Aggregate

A unified app to track all the health metrics and vitals collected from various DrTrust devices

Access


Consult specialists from top hospitals, book diagnostics and lab services

Interact

Share real time health data with doctors nutritionist and health guardians

Engage

Personalised recipes, nutrition and workout videos targeted around user goals



On our smart healthcare platform, Dr Trust 360, we have a series of value-added features:


Virtual Care & Telehealth

Dr Trust 360 now makes it easy to consult leading doctors at the comfort and convenience of your home via a video call. Our nutrition plans, combine behavioral psychology, technology, and live nutritionists coaching, helping our users in their weight management journey.




Health guardians

Add your health guardians so that they can be in the loop with the progress you make. Your health guardians shall receive whatsapp alerts at the right time when your readings are not in range.



Track your daily calories & Nutritional Support

Add and track your daily meals with our nutrition database with over 1,00,000+ Indian and global food items. Set your daily calorie intake goal and better understand your macro nutrient intake too. For better health management, platform provides nutritional support to our users with customised diet plan, calories tracking and dedicated nutritionist to guide our users achieved better results




DrTrust 360 Holistic Solutions

On our smart healthcare platform, Dr Trust 360, we have a series of value-added features :


Measure health data

Dr Trust 360 now makes it easy to measure weight, blood pressure, blood sugar, etc via DrTrust devices




Analyse

Dr Trust 360 platform now enables user to derive interactive actionable insights & trends to better manage their health




Smart Sensei™ Technology

Enabling direct capture of vitals from non-connected devices without any manual intervention




DrTrust 360 Holistic Solutions

During the quarter, we have added more value-added features:




User Onboarding

Revamped onboarding flow by reducing complications and personalizing it further based on User's end goal.



Home

The banner section on the top now help integrate the Dr Trust store and also run multiple campaigns promoting our smart diet plan.



Nutrition UI

A new nutrition logging UI is now introduced to help make food logging into a better user experience

Nureca Technologies – ISO 13485 and 9001 Certification

Nureca Technologies Private Limited, a Wholly owned subsidiary of Nureca Limited, has obtained ISO 13485:2016 and ISO 9001:2015 certifications from notified body Intertek, for Nebulizers and Blood pressure monitors.

These certifications represents another key milestone for the Company's globally certified made in India medical devices manufacturing site. It will open new avenues for the Company's flagship brand "Dr Trust", enabling to export these devices to many more countries. These certifications solidifies the Company's commitment to quality and compliance in the world of health.

intertek
Total Quality. Assured.

CERTIFICATE OF REGISTRATION

This is to certify that the management system of:

NURECA TECHNOLOGIES PVT. LTD.

Main Site: Plot No. 99, 100, Sector 82, JLPL, Mohali SAS Nagar, Mohali - 160055, Punjab, India

has been registered by Intertek as conforming to the requirements of:

ISO 13485:2016

The management system is applicable to:

Design, Development, Manufacture and Despatch of Nebulizer and Blood Pressure Monitor.

Certificate Number: 0129099

Initial Certification Date: 07 October 2022

Date of Certification Decision: 07 October 2022

Issuing Date: 07 October 2022

Valid Until: 06 October 2025



Calin Moldovean

Calin Moldovean
President, Business Assurance

Intertek India Private Limited, F-Wing, 2nd Floor, Tax Centre, Chandivall Farm Road, Anandhi (East), Mumbai - 400072, India

Intertek India Private Limited is a NABCB accredited body under schedule of accreditation no. QM033.



In the issuance of this certificate, Intertek assumes no liability to any party other than to the Client, and then only in accordance with the agreed upon Certification Agreement. This certificate's validity is subject to the organization maintaining their system in accordance with Intertek's requirements for systems certification. Validity may be confirmed via email at certificate.validation@intertek.com or by scanning the code to the right with a smartphone. The certificate remains the property of Intertek, to whom it must be returned upon request.



intertek
Total Quality. Assured.

CERTIFICATE OF REGISTRATION

This is to certify that the management system of:

NURECA TECHNOLOGIES PVT. LTD.

Main Site: Plot No. 99, 100, Sector 82, JLPL, Mohali SAS Nagar, Mohali - 160055, Punjab, India

has been registered by Intertek as conforming to the requirements of:

ISO 9001:2015

The management system is applicable to:

Design, Development, Manufacture and Dispatch of Nebulizer and Blood Pressure Monitor.

Certificate Number: 0327215

Initial Certification Date: 29 August 2022

Date of Certification Decision: 29 August 2022

Issuing Date: 29 August 2022

Valid Until: 28 August 2025



Calin Moldovean

Calin Moldovean
President, Business Assurance

Intertek Certification Limited, 10A Victory Park, Victory Park, Derby DE24 8EP, United Kingdom

Intertek Certification Limited is a UKAS accredited body under schedule of accreditation no. 034.



In the issuance of this certificate, Intertek assumes no liability to any party other than to the Client, and then only in accordance with the agreed upon Certification Agreement. This certificate's validity is subject to the organization maintaining their system in accordance with Intertek's requirements for systems certification. Validity may be confirmed via email at certificate.validation@intertek.com or by scanning the code to the right with a smartphone. The certificate remains the property of Intertek, to whom it must be returned upon request.






What Makes Nureca Different?

Product Quality

- International standards quality and design of the products

Regulatory Compliance

- Our products are manufactured to be safe, accurate, long-lasting and compliant to national and international regulations. Our chronic monitoring devices are USFDA approved.



Wide product range

- Nureca offers an entire bouquet of digital home healthcare devices

Price-value proposition

- Superior consumer price-value proposition with stringent quality control

Brand Loyalty

- Over the course of last 5 years, Nureca has generated a loyal customer base of over 8 million customers

Focused digital strategy

- Emphasis on 'Point of Sales' (POS) marketing via online channels; Videos on digital shelf and YouTube channel; Presence across multiple digital media; Strong emphasis on search engine optimisation (SEO).

Business Outlook

ADDING PRODUCTS AND CATEGORIES

- Strong focus on connected devices for remote patient monitoring
- Create a pipeline of innovative healthcare and wellness products
- A strong customer base for cross-selling of different products

OFFLINE EXPANSION

- Increase tie-ups with modern retail brands, pharmacy chains, hospital chains and leading electronics chains.

MARKETING


- Increase online and offline advertising
- Increase influencer marketing
- The Company plans to leverage data analytics and artificial intelligence for higher conversions

With the launch of our connected devices eco system, we will leverage data science capabilities to empower more people living with chronic and lifestyle diseases to live better and healthier lives. Our software will analyze clinical data and apply iterative insights to our user's lifestyle to deliver a more personalized care experience. This will reinforce our theme of shifting India's healthcare sector from curative to preventive and further from preventive to pre-diagnostics. We will be one step closer to our goal of making a positive impact on the lifestyle and health of our esteemed users and eventually enhance the longevity of their lives. We are working with various partners and building capabilities to provide all healthcare services on our Dr. Trust 360 platform with affordable subscription rate which will change our business model from being product driven company to services driven company.



Shareholder Information

Shareholding as on 30th September 2022



Share Information as on 30th September 2022

NSE Ticker	NURECA
BSE Ticker	543264
IPO Listing Date	25 th February 2021
Market Cap (INR Cr)	890
Share Price (INR)	890
Shares Outstanding	1,00,00,175
Industry	Healthcare

Thank .
You .

INVESTOR RELATIONS AT NURECA

Gurvikram Singh
cs@nureca.com

Office No. 101, Udyog
Bhavan, Sonawala Lane,
Goregaon East, Mumbai,
Maharashtra - 400063

Drtrust.in Drtrust360.com



Trust whats best for your family!